Beam Therapeutics Company Leadership

BEAM Stock  USD 27.37  0.17  0.63%   
Beam Therapeutics' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Beam Therapeutics suggests that most insiders are panicking. Beam Therapeutics employs about 472 people. The company is managed by 15 executives with a total tenure of roughly 1102 years, averaging almost 73.0 years of service per executive, having 31.47 employees per reported executive.

Beam Therapeutics' Insider Buying Vs Selling

0

 
Selling
 
Buying

Latest Trades

2024-11-06Giuseppe CiaramellaDisposed 51110 @ 26.36View
2024-10-14Giuseppe CiaramellaDisposed 51110 @ 26.27View
2024-10-01Christine BellonDisposed 385 @ 23.48View
2024-09-30John M EvansDisposed 60000 @ 24.6View
2024-07-01Amy SimonDisposed 502 @ 23.76View
2024-06-27John M EvansDisposed 60000 @ 24.5View
2024-04-01Terry-Ann BurrellDisposed 5446 @ 32.12View
2024-03-28John M EvansDisposed 60000 @ 33.86View
2024-02-13Fmr LlcDisposed 1565 @ 30.76View
2024-01-31John M EvansDisposed 60000 @ 25.33View
2024-01-03Christine BellonDisposed 1907 @ 26.42View
Monitoring Beam Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Beam Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.

Beam Therapeutics' Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Beam Therapeutics' future performance. Based on our forecasts, it is anticipated that Beam will maintain a workforce of about 470 employees by January 2025.
 
Covid

Beam Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of (0.0928) % which means that it has lost $0.0928 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1829) %, meaning that it created substantial loss on money invested by shareholders. Beam Therapeutics' management efficiency ratios could be used to measure how well Beam Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 1st of December 2024, Return On Tangible Assets is likely to drop to -0.1. In addition to that, Return On Capital Employed is likely to grow to -0.13. At this time, Beam Therapeutics' Other Current Assets are very stable compared to the past year. As of the 1st of December 2024, Total Current Assets is likely to grow to about 1.3 B, while Non Current Assets Total are likely to drop about 193.3 M.
As of the 1st of December 2024, Common Stock Shares Outstanding is likely to drop to about 56.2 M. In addition to that, Net Loss is likely to drop to about (245.9 M)

Beam Therapeutics Workforce Comparison

Beam Therapeutics is rated fourth in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 9,444. Beam Therapeutics holds roughly 472 in number of employees claiming about 5% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.41) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (7.46) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $7.46.

Beam Therapeutics Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Beam Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Beam Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Beam Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2024-12-01
0.4286
3
7
 41,754 
 144,648 
2024-09-01
0.2222
2
9
 7,500 
 144,292 
2024-06-01
1.7143
12
7
 369,782 
 115,170 
2024-03-01
1.4286
10
7
 585,000 
 1,023,472 
2023-12-01
0.5
4
8
 139,946 
 144,285 
2023-09-01
0.5
3
6
 92,490 
 249,411 
2023-06-01
0.4545
5
11
 82,660 
 38,157 
2023-03-01
0.7241
21
29
 520,371 
 619,540 
2022-12-01
0.2
3
15
 31,363 
 150,589 
2022-09-01
2.0
16
8
 1,003,425 
 1,400,029 
2022-06-01
0.4444
4
9
 1,084,861 
 1,652,383 
2022-03-01
0.4375
7
16
 358,750 
 159,907 
2021-12-01
0.3
6
20
 112,533 
 191,100 
2021-09-01
0.4043
19
47
 5,480,233 
 9,132,804 
2021-06-01
0.6458
31
48
 248,648 
 3,562,250 
2021-03-01
0.9259
25
27
 763,218 
 3,654,030 
2020-12-01
0.0952
2
21
 55,842 
 121,984 
2020-09-01
1.5
3
2
 367,714 
 11,040 
2020-06-01
1.0
1
1
 115,000 
 115,000 
2020-03-01
0.6552
19
29
 34,793,667 
 55,823,725 

Beam Therapeutics Notable Stakeholders

A Beam Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Beam Therapeutics often face trade-offs trying to please all of them. Beam Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Beam Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.

About Beam Therapeutics Management Performance

The success or failure of an entity such as Beam Therapeutics often depends on how effective the management is. Beam Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Beam management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Beam management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.09)(0.10)
Return On Capital Employed(0.14)(0.13)
Return On Assets(0.09)(0.10)
Return On Equity(0.14)(0.14)

Beam Therapeutics Workforce Analysis

Traditionally, organizations such as Beam Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Beam Therapeutics within its industry.

Beam Therapeutics Manpower Efficiency

Return on Beam Therapeutics Manpower

Revenue Per Employee800.2K
Revenue Per Executive25.2M
Net Loss Per Employee280.8K
Net Loss Per Executive8.8M
Working Capital Per Employee2.1M
Working Capital Per Executive67M
When determining whether Beam Therapeutics is a strong investment it is important to analyze Beam Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Beam Therapeutics' future performance. For an informed investment choice regarding Beam Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Beam Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.
You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Beam Therapeutics. If investors know Beam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Beam Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.58)
Revenue Per Share
4.273
Quarterly Revenue Growth
(0.17)
Return On Assets
(0.09)
Return On Equity
(0.18)
The market value of Beam Therapeutics is measured differently than its book value, which is the value of Beam that is recorded on the company's balance sheet. Investors also form their own opinion of Beam Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Beam Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Beam Therapeutics' market value can be influenced by many factors that don't directly affect Beam Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Beam Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Beam Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Beam Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.